Fig. 4

Interactions formed between DTG and the energy minimized WT and seven mutant structures for HIV-1 CRF02_AG Integrase. a WT HIV-1 CRF02_AG IN showing in total six contacts formed between DTG and two IN residues, two DNA nucleotides and two MG ions. b T66A HIV-1 CRF02_AG IN showing in total four contacts formed between DTG and one IN residue, one DNA nucleotide and two MG ions. c T97A HIV-1 CRF02_AG IN showing in total five contacts formed between DTG and two IN residues, one DNA nucleotide and two MG ions. d E157Q HIV-1 CRF02_AG IN showing in total four contacts formed between DTG and one IN residue, two DNA nucleotides and one MG ion. e Q148H HIV-1 CRF02_AG IN showing in total five contacts formed between DTG and one IN residue, two DNA nucleotides and two MG ions. f R263K HIV-1 CRF02_AG IN showing in total four contacts formed between DTG and one IN residue, one DNA nucleotide and two MG ions. g N155H HIV-1 CRF02_AG IN showing in total seven contacts formed between DTG and three IN residues, two DNA nucleotides and two MG ions. h D232N HIV-1 CRF02_AG IN showing in total two contacts formed between DTG and two DNA nucleotides. The drug DTG is shown as sticks and coloured in magenta, the MG ions are shown as spheres coloured in green while the IN protein residues and terminal 3’end viral DNA nucleotides are labelled and shown as sticks. Three letter codes for IN protein residues and numbers are given as well as the DNA nucleotide three letter codes and numbers. The nucleotides represent terminal end viral DNA nucleotides after 3′ processing